The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "M15 General Principles for Model-Informed Drug Development." The guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The guidance provides general recommendations for the planning, model evaluation, and documentation of evidence derived from model-informed drug development (MIDD). It establishes a harmonized assessment framework (including the associated terminology) for the MIDD evidence. It also provides recommendations for related regulatory interactions, reporting, and submission. This guideline is intended to facilitate a multidisciplinary understanding of MIDD and associated evidence generation. The guidance finalizes the draft guidance of the same title issued on December 30, 2024.
US Federal Register - FDA Guidance Notices · June 03, 2026
M15 General Principles for Model-Informed Drug Development; ICH Guidance for Industry
Original title: M15 General Principles for Model-Informed Drug Development; International Council for Harmonisation; Guidance for Industry; Availability
FDA finalizes ICH M15 guidance on model-informed drug development planning, evaluation, documentation, and regulatory submission.
Published by US Federal Register - FDA Guidance Notices. HealthSignal links to the original document; the summary above is extracted from the source text.